ALK raises minimum full-year sales guidance after Q3
The allergy group now expects organic revenue growth of 11-13% compared to a previous 10-13% in local currencies. However, tablet sales are expected to disappoint.
by marketwire and mikkel aabenhus hemmingsen, translated by catherine brett
ALK did better than expected during Q3, 2022, both in terms of earnings and revenue.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK expands Danish headquarters
For subscribers
